A Phase 1/2 interventional study of tamsolusin and prazosin in Neurogenic Bladder, sponsored by Tabriz University. Status unknown. Open to female participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2008-01-29.
Sponsored by Tabriz University · Phase 1/2, Interventional, and Treatment
The purpose of this study is to determine whether Tamsolusin or Prazosin are effective in the treatment of female voiding dysfunction(BOO)
Voiding dysfunction is not uncommon in Tabriz.About 20% of patients in female urology clinic of Tabriz university of medical sciences sufered from some degrees of voiding dysfunction (due to bladder imparement or bladder outlet obstruction).There is limited information about medical treatment of those patients. On the other hand alpha adrenergic blockers are the first choice medication in BENIGN PROSTATIC HYPERPLASIA. There is some new facts about destribution of alpha adrenergic blockers in female pelvic floor.The purpose of this study is to comparision whether Tamsolusin 0.4/daily or Prazosin 1 mg/daily are effective in the treatment of female voiding dysfunction(BOO)
185 studies on the registry are indexed under Urinary Bladder, Neurogenic; 40 are open to participants now.
This study's enrollment of 80 is above the median of 36 across 124 interventional studies indexed under Urinary Bladder, Neurogenic.
Browse Urinary Bladder, Neurogenic studies →Tabriz University is the lead sponsor of 15 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
taking Tamsulosin
Drug: tamsolusin
taking prasosin
Drug: prazosin
0.4 mg /day
Also known as: Flomax
1 mg/day
patient symptoms improvement(Standard questionare)
Time frame: every month untile 3 months
Urodynamics parameters improvement
Time frame: three months later
No study locations are listed for this record.
This study is status unknown, as verified in Jan 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tabriz University